Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
Purpose
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8
- Anatomic Stage 1 Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Estrogen Receptor-Positive Breast Carcinoma
- HER2-Negative Breast Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Unilateral invasive adenocarcinoma of the breast that is histologically confirmed
- Invasive breast cancer is estrogen receptor positive in ≥ 10% of cells
- HER2 negative by current American Society of Clinical Oncology (ASCO)/College
of American Pathologists (CAP) guidelines
- The patient must have a multigene assay with a low-risk score, including any of the
following (if more than one genomic assay was obtained, both are required to be
low-risk):
- Oncotype DX recurrence score ≤ 25
- Mamma Print low risk
- Prosigna risk of recurrence ≤ 40
- Tumor size must be ≤ 3 cm by pathologic evaluation
- Adequate surgical removal of all clinically evident disease in the breast with
either breast conserving surgery or mastectomy. Negative margins on final pathology
are required. Additional excisions may be performed to obtain clear margins before
registration
- No clinical (cN1, cN2, cN3) or pathologic (pN1mi, pN1, pN2, or pN3) evidence of
lymph node involvement on either needle biopsy or surgical lymph node assessment.
Patients with pN0(i+) or pN0 (mol+) are eligible
- Surgical axillary staging (sentinel lymph node biopsy ± axillary lymph node
dissection) is completed according to physician discretion
- For patients with negative preoperative axillary ultrasonography, clinicians
may selectively choose to forego surgical axillary staging. Ipsilateral
axillary ultrasound showing no lymph node involvement with no evidence of
lymphadenopathy or suspicious thickening is required in this scenario
- No pathological tumor size > 3 cm or pT4
- No definitive clinical or radiologic evidence of metastatic disease
- No palpable or radiographically suspicious axillary, supraclavicular,
infraclavicular, or internal mammary lymph nodes, unless there is histologic
confirmation that these lymph nodes are negative for tumor
- No suspicious microcalcifications, densities, or palpable abnormalities in the
ipsilateral or contralateral breast, unless biopsied and found to be benign
- An interval of no more than 20 weeks between the date of surgery and the date of
registration
- Must have had a bilateral mammogram or MRI within 6 months prior to registration
- Must be intending to take endocrine therapy for at least 5 years duration
- No prior treatment with endocrine therapy or chemotherapy for the currently
diagnosed breast cancer prior to registration. (Short course endocrine therapy of ≤
6 weeks duration is acceptable after core biopsy and before surgery, if genomic
testing is assessed on the biopsy core and meets eligibility requirements for a
low-risk score.)
- No use of oral hormone replacement therapy within 7 days prior to registration
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Postmenopausal status confirmed as:
- No spontaneous menses ≥ 1 year
- No menses for < 1 year with follicle stimulating hormone (FSH) and estradiol
levels within a postmenopausal range according to institutional standards
- Previous bilateral surgical oophorectomy
- None of the following conditions:
- Abnormal or dysfunctional uterine bleeding within 1 year prior to study
enrollment
- Any patient with known atypia or endometrial pathology that the opinion of the
treating investigator would place the patient at undue risk of endometrial
cancer with tamoxifen.
- Any patient with a known hypercoagulable state that in the opinion of the
treating investigator would put the patient at undue risk of venous
thromboembolism with tamoxifen
- No history of breast or thoracic radiotherapy for any previous condition. Patients
may complete radiotherapy for the currently diagnosed breast cancer prior to
registering for the study. In this scenario, registration must be completed within
12 weeks of completing breast radiotherapy
- No previous history of ipsilateral invasive breast cancer or ipsilateral ductal
carcinoma in situ (DCIS), regardless of the disease-free interval
- No synchronous or previous contralateral invasive or non-invasive breast cancer
- Patients with a prior or concurrent malignancy whose natural history or treatment
does not have the potential to interfere with the safety or efficacy assessment of
the investigational regimen are eligible for this trial
- No patients with premenopausal status
- No current treatment with any endocrine therapy for breast cancer prevention or
osteoporosis, including raloxifene, tamoxifen, or other selective estrogen receptor
modulator. Patients intending to continue oral hormone replacement are not eligible
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral
load within 6 months are eligible for this trial
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (anastrozole, letrozole, exemestane, tamoxifen) |
Patients receive standard of care endocrine therapy per physician choice with either anastrozole PO, letrozole PO, exemestane PO or standard dose tamoxifen PO QD for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients may also undergo mammogram or MRI, DEXA, and blood sample collection on study. |
|
Experimental Arm II (low dose tamoxifen) |
Patients receive low-dose tamoxifen PO QOD for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients may also undergo mammogram or MRI, DEXA, and blood sample collection on study. |
|
Recruiting Locations
Anchorage, Alaska 99508
Phoenix, Arizona 85054
Site Public Contact
855-776-0015
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Jonesboro, Arkansas 72401
Beverly Hills, California 90211
Buena Park, California 90621
Site Public Contact
714-522-0908
Cameron Park, California 95682
Chico, California 95926
Site Public Contact
530-332-4700
Dublin, California 94568
Site Public Contact
877-642-4691
Fremont, California 94538
Fresno, California 93720
Irvine, California 92612
Los Angeles, California 90033
Los Angeles, California 90033
Site Public Contact
323-865-0451
Los Angeles, California 90048
Site Public Contact
310-423-8965
Marysville, California 95901
Site Public Contact
530-749-4400
Modesto, California 95356
Newport Beach, California 92663
Site Public Contact
323-865-0451
Oakland, California 94611
Orange, California 92868
Pasadena, California 91105
Site Public Contact
626-535-2420
Rancho Mirage, California 92270
Site Public Contact
760-834-3798
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95817
Site Public Contact
916-734-3089
Sacramento, California 95823
Saint Helena, California 94574
Site Public Contact
707-967-3698
San Diego, California 92123
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Rafael, California 94903
Santa Clara, California 95051
Santa Rosa, California 95403
South San Francisco, California 94080
Tarzana, California 91356
Site Public Contact
818-981-3818
Torrance, California 90505
Truckee, California 96161
Site Public Contact
530-582-6450
Vallejo, California 94589
Walnut Creek, California 94596
Yorba Linda, California 92886
Brighton, Colorado 80601
Denver, Colorado 80218
Golden, Colorado 80401
Grand Junction, Colorado 81501
Lafayette, Colorado 80026
Danbury, Connecticut 06810
Site Public Contact
203-739-8074
Derby, Connecticut 06418
Fairfield, Connecticut 06824
Glastonbury, Connecticut 06033
Greenwich, Connecticut 06830
Guilford, Connecticut 06437
Hartford, Connecticut 06105
New Haven, Connecticut 06520
North Haven, Connecticut 06473
Norwalk, Connecticut 06856
Stamford, Connecticut 06902
Stamford, Connecticut 06904
Site Public Contact
203-323-8944
Torrington, Connecticut 06790
Trumbull, Connecticut 06611
Waterbury, Connecticut 06708
Waterford, Connecticut 06385
Dover, Delaware 19901
Milford, Delaware 19963
Millville, Delaware 19967
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Washington, District of Columbia 20002
Clearwater, Florida 33756
Site Public Contact
855-314-8646
Gainesville, Florida 32610
Jacksonville, Florida 32224-9980
Site Public Contact
855-776-0015
Saint Petersburg, Florida 33705
Winter Haven, Florida 33881
Albany, Georgia 31701
Honolulu, Hawaii 96819
Coeur d'Alene, Idaho 83814
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Aurora, Illinois 60506
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60611
Chicago, Illinois 60637
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
DeKalb, Illinois 60115
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Geneva, Illinois 60134
Glenview, Illinois 60026
Site Public Contact
312-695-1102
Grayslake, Illinois 60030
Site Public Contact
312-695-1102
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Macomb, Illinois 61455
Mattoon, Illinois 61938
Moline, Illinois 61265
Site Public Contact
309-779-2000
New Lenox, Illinois 60451
O'Fallon, Illinois 62269
Oak Brook, Illinois 60523
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Orland Park, Illinois 60462
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Rockford, Illinois 61108
Site Public Contact
815-227-2633
Rockford, Illinois 61114
Shiloh, Illinois 62269
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Warrenville, Illinois 60555
Washington, Illinois 61571
Avon, Indiana 46123
Carmel, Indiana 46032
Crown Point, Indiana 46307
Indianapolis, Indiana 46202
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Boone, Iowa 50036
Site Public Contact
515-956-4132
Carroll, Iowa 51401
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Clive, Iowa 50325
Site Public Contact
515-241-3305
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Waukee, Iowa 50263
Site Public Contact
515-241-3305
Kansas City, Kansas 66160
Overland Park, Kansas 66210
Overland Park, Kansas 66211
Westwood, Kansas 66205
New Orleans, Louisiana 70121
Brewer, Maine 04412
Site Public Contact
800-987-3005
Baltimore, Maryland 21244
Cumberland, Maryland 21502
Site Public Contact
240-964-1400
Gaithersburg, Maryland 20879
Largo, Maryland 20774
Lutherville, Maryland 21093
Lowell, Massachusetts 01854
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Canton, Michigan 48188
Chelsea, Michigan 48118
Detroit, Michigan 48236
East China Township, Michigan 48054
Escanaba, Michigan 49829
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Lansing, Michigan 48912
Livonia, Michigan 48154
Macomb, Michigan 48044
Macomb, Michigan 48044
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Pontiac, Michigan 48341
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Warren, Michigan 48093
Warren, Michigan 48093
Warren, Michigan 48093
Wyoming, Michigan 49519
Ypsilanti, Michigan 48197
Albert Lea, Minnesota 56007
Site Public Contact
855-776-0015
Brainerd, Minnesota 56401
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Mankato, Minnesota 56001
Site Public Contact
855-776-0015
Rochester, Minnesota 55905
Site Public Contact
855-776-0015
Saint Cloud, Minnesota 56303
Sandstone, Minnesota 55072
Virginia, Minnesota 55792
Columbus, Mississippi 39705
Grenada, Mississippi 38901
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Osage Beach, Missouri 65065
Saint Louis, Missouri 63110
Saint Louis, Missouri 63128
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63136
Saint Peters, Missouri 63376
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Billings, Montana 59102
Site Public Contact
800-648-6274
Bozeman, Montana 59715
Great Falls, Montana 59405
Missoula, Montana 59804
Concord, New Hampshire 03301
Site Public Contact
603-224-2556
Manchester, New Hampshire 03103
Site Public Contact
800-339-6484
Cherry Hill, New Jersey 08002
Freehold, New Jersey 07728
Site Public Contact
732-303-5047
Hackensack, New Jersey 07601
Site Public Contact
551-996-2897
Morristown, New Jersey 07960
Site Public Contact
973-971-5900
Sewell, New Jersey 08080
Summit, New Jersey 07902
Site Public Contact
908-522-2043
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87106
Albuquerque, New Mexico 87109
Albuquerque, New Mexico 87110
Rio Rancho, New Mexico 87124
Buffalo, New York 14263
Camillus, New York 13031
Site Public Contact
315-472-7504
East Syracuse, New York 13057
Site Public Contact
315-472-7504
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Asheville, North Carolina 28803
Chapel Hill, North Carolina 27599
Charlotte, North Carolina 28204
Clyde, North Carolina 28721
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Hendersonville, North Carolina 28791
Hendersonville, North Carolina 28792
Huntersville, North Carolina 28078
Kernersville, North Carolina 27284
Matthews, North Carolina 28105
Mooresville, North Carolina 28117
Mount Airy, North Carolina 27030
Raleigh, North Carolina 27607
Site Public Contact
919-785-4878
Thomasville, North Carolina 27360
Weaverville, North Carolina 28787
Winston-Salem, North Carolina 27103
Fargo, North Dakota 58103
Akron, Ohio 44304
Barberton, Ohio 44203
Canton, Ohio 44710
Centerville, Ohio 45459
Cincinnati, Ohio 45219
Cincinnati, Ohio 45220
Columbus, Ohio 43210
Dayton, Ohio 45409
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45415
Franklin, Ohio 45005-1066
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Medina, Ohio 44256
Troy, Ohio 45373
West Chester, Ohio 45069
Oklahoma City, Oklahoma 73104
Bend, Oregon 97701
Corvallis, Oregon 97330
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Hood River, Oregon 97031
Newberg, Oregon 97132
Oregon City, Oregon 97045
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Beaver, Pennsylvania 15009
Chambersburg, Pennsylvania 17201
Site Public Contact
717-217-6020
Cranberry Township, Pennsylvania 16066
Danville, Pennsylvania 17822
Ephrata, Pennsylvania 17522
Site Public Contact
717-721-4840
Erie, Pennsylvania 16505
Farrell, Pennsylvania 16121
Gettysburg, Pennsylvania 17325
Site Public Contact
877-441-7957
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Harrisburg, Pennsylvania 17109
Johnstown, Pennsylvania 15901
Site Public Contact
814-534-4724
Lebanon, Pennsylvania 17042
Lewisburg, Pennsylvania 17837
Mechanicsburg, Pennsylvania 17050
Monroeville, Pennsylvania 15146
Moon, Pennsylvania 15108
N. Huntingdon, Pennsylvania 15642
Natrona Heights, Pennsylvania 15065
Site Public Contact
724-230-3030
New Castle, Pennsylvania 16105
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19114
Phoenixville, Pennsylvania 19460
Site Public Contact
610-983-1800
Pittsburgh, Pennsylvania 15213
Site Public Contact
412-647-2811
Pittsburgh, Pennsylvania 15215
Site Public Contact
412-784-4900
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pittsburgh, Pennsylvania 15237
Site Public Contact
412-367-6454
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
Seneca, Pennsylvania 16346
Site Public Contact
814-676-7900
Uniontown, Pennsylvania 15401
Washington, Pennsylvania 15301
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Williamsport, Pennsylvania 17754
Willow Grove, Pennsylvania 19090
Providence, Rhode Island 02905
Site Public Contact
401-274-1122
Westerly, Rhode Island 02891
Boiling Springs, South Carolina 29316
Site Public Contact
864-241-6251
Easley, South Carolina 29640
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29615
Site Public Contact
864-241-6251
Greenwood, South Carolina 29646
Greer, South Carolina 29650
Site Public Contact
864-241-6251
Seneca, South Carolina 29672
Site Public Contact
864-241-6251
West Columbia, South Carolina 29169
Rapid City, South Dakota 57701
Collierville, Tennessee 38017
Memphis, Tennessee 38120
Amarillo, Texas 79106
Baytown, Texas 77521
Conroe, Texas 77384
Cypress, Texas 77429
Galveston, Texas 77555-0565
Houston, Texas 77030
Site Public Contact
713-790-2700
Houston, Texas 77030
Houston, Texas 77070
Houston, Texas 77079
Houston, Texas 77094
Site Public Contact
832-522-2873
League City, Texas 77573
Nassau Bay, Texas 77058
Sugar Land, Texas 77478
Sugar Land, Texas 77479
Site Public Contact
281-242-2873
The Woodlands, Texas 77385
Burlington, Vermont 05401
Burlington, Vermont 05405
Fishersville, Virginia 22939
Site Public Contact
540-332-5960
McLean, Virginia 22102
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23226
Woodbridge, Virginia 22192
Edmonds, Washington 98026
Issaquah, Washington 98029
Seattle, Washington 98122
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Morgantown, West Virginia 26506
Parkersburg, West Virginia 26101
Princeton, West Virginia 24740
Site Public Contact
304-487-7515
Wheeling, West Virginia 26003
Site Public Contact
304-243-6442
Antigo, Wisconsin 54409
Appleton, Wisconsin 54911
Appleton, Wisconsin 54915
Ashland, Wisconsin 54806
Brookfield, Wisconsin 53045
Burlington, Wisconsin 53105
Chilton, Wisconsin 53014
Cudahy, Wisconsin 53110
Eau Claire, Wisconsin 54701
Site Public Contact
855-776-0015
Franklin, Wisconsin 53132
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Site Public Contact
855-776-0015
Marinette, Wisconsin 54143
Medford, Wisconsin 54451
Mequon, Wisconsin 53097
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53211
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53233
Mukwonago, Wisconsin 53149
New Richmond, Wisconsin 54017
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oconto Falls, Wisconsin 54154
Oshkosh, Wisconsin 54904
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53405
Racine, Wisconsin 53406
Rhinelander, Wisconsin 54501
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54481
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Waukesha, Wisconsin 53188
Site Public Contact
262-928-7632
Waukesha, Wisconsin 53188
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wauwatosa, Wisconsin 53226
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
Manati, Puerto Rico 00674
Site Public Contact
787-621-4397
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- NCT ID
- NCT06671912
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
The primary and secondary objectives of the study: PRIMARY OBJECTIVE: I. To evaluate whether the recurrence-free interval (RFI) with low-dose tamoxifen is non-inferior to standard-of-care endocrine therapy among post-menopausal women with early-stage, low molecular risk breast cancer. SECONDARY OBJECTIVES: I. To compare endocrine therapy nonadherence rates between treatment arms. II. To compare the incidence of adverse events between treatment arms, including osteoporosis, fracture, endometrial carcinoma, stroke, and deep vein thrombosis. III. To compare endocrine therapy-related patient reported symptoms between treatment arms. IV. To compare the invasive disease-free survival between treatment arms. V. To compare the locoregional breast cancer recurrence between treatment arms. VI. To compare distant recurrence free survival between treatment arms. VII. To compare overall survival between treatment arms. VIII. To compare ductal carcinoma in situ (DCIS) incidence (ipsilateral and contralateral) between treatment arms. IX. To evaluate the association between radiotherapy modality (no radiation, partial breast radiation, and whole breast radiation) and RFI in each arm. X. To explore important measures of quality of life that would reasonably be expected to vary by study arm, including global quality of life and reasons for nonadherence. XI. To compare change in mammographic density at two years between treatment arms. XII. To conduct a within patient comparison of automated versus (vs) semi-automated mammographic density determination. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive standard of care endocrine therapy per physician choice with either anastrozole orally (PO), letrozole PO, exemestane PO or standard dose tamoxifen PO once daily (QD) for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients may also undergo mammogram or magnetic resonance imaging (MRI), dual X-ray absorptiometry (DEXA), and blood sample collection on study. ARM II: Patients receive low-dose tamoxifen PO every other day (QOD) for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients may also undergo mammogram or MRI, DEXA, and blood sample collection on study. After completion of study treatment, patients are followed up for 10 years after registration.